A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for the clinical-stage ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with ...

If your drug trials don't succeed, try again with another drug — and raise more money. That's $RAPT's plan as it targets food ...

Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - SOUTH SAN FRANCISCO, Calif., ...

INR:9518. my available time slots Novartis' next-generation IgE antibody therapy receives FDA breakthrough therapy designation China's first COVID-19 reco ...

RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies.

INR:3073. slots 777 big win The combination therapy of anti-HER2 bispecific antibody KN026 and Ibrance has been approved for clinical trials More than 3,000 pha ...